Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Pharmorubicin RDF (epirubicin)
- sargramostim
Interactions between your drugs
sargramostim epiRUBicin
Applies to: sargramostim, Pharmorubicin RDF (epirubicin)
ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.
MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.
References (4)
- (2002) "Product Information. Neupogen (filgrastim)." Amgen
- (2001) "Product Information. Leukine (sargramostim)." Immunex Corporation
- (2001) "Product Information. Stemgen (ancestim)." Amgen
- (2013) "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Herceptin
Herceptin is used to treat patients with metastatic breast cancer. Learn about side effects ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Taxol
Taxol (paclitaxel) is used to treat breast cancer, lung cancer, and ovarian cancer. Includes Taxol ...
Nolvadex
Nolvadex is used for breast cancer, breast cancer, adjuvant, breast cancer, male, breast cancer ...
Trazimera
Trazimera (trastuzumab-qyyp) is a biosimilar to Herceptin that may be used to treat certain types ...
Nerlynx
Nerlynx (neratinib) is used for the extended adjuvant treatment of early-stage, HER2-positive ...
Ontruzant
Ontruzant is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, esophageal ...
Kanjinti
Kanjinti is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, esophageal ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.